TY - JOUR
T1 - Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species
AU - Yokoyama, Misa
AU - Tanuma, Nobuhiro
AU - Shibuya, Rie
AU - Shiroki, Takeharu
AU - Abue, Makoto
AU - Yamamoto, Kuniharu
AU - Miura, Koh
AU - Yamaguchi, Kazunori
AU - Sato, Ikuro
AU - Tamai, Keiichi
AU - Satoh, Kennichi
N1 - Funding Information:
This study was supported by Grants-in-Aid for scientific Research (KAKENhI) (nos. 15K19080 and 15K09055) to MY and Ks, respectively.
PY - 2018/3
Y1 - 2018/3
N2 - The majority of cancer cells maintain a high glycolytic activity and an increased lactate production, even in a well oxygenated environment. This phenomenon is known as the Warburg effect. Previous studies have revealed that various types of cancer selectively express the pyruvate kinase M2 isoform (PKM2), and that PKM2 plays a pivotal role in the Warburg effect. Although elevated PKM2 levels have been observed in pancreatic cancer and other types of cancer, little is known about the biological function of PKM2. In this study, in order to examine the expression and role of PKM2 in pancreatic ductal adenocarcinoma (PDAC), we knocked down PKM2 in PDAC cells by introducing small interfering and short hairpin RNAs, and examined the gene expression profiles in the cells by microarray analysis. We analyzed the energy-producing pathways in the cells by XFe Extracellular Flux Analyzers, and detected intracellular metabolites by capillary electrophoresis time-of-flight mass spectrometry. We found that the RNAi-mediated knockdown of PKM2 diminished the proliferative, migratory and tumorigenic ability of the PDAC cell-lines. PKM2 knockdown also resulted in lower glycolytic activities and decreased levels of some intracellular metabolites, such as pyruvate and polyamine; however, it led to elevated levels of reactive oxygen species. Microarray analysis revealed the functional association between PKM2 and the expression of genes that drive the cell cycle. On the whole, the findings of this study demonstrate that PKM2 plays an important role in metabolic activities, as well as in the malignancy of PDAC cells.
AB - The majority of cancer cells maintain a high glycolytic activity and an increased lactate production, even in a well oxygenated environment. This phenomenon is known as the Warburg effect. Previous studies have revealed that various types of cancer selectively express the pyruvate kinase M2 isoform (PKM2), and that PKM2 plays a pivotal role in the Warburg effect. Although elevated PKM2 levels have been observed in pancreatic cancer and other types of cancer, little is known about the biological function of PKM2. In this study, in order to examine the expression and role of PKM2 in pancreatic ductal adenocarcinoma (PDAC), we knocked down PKM2 in PDAC cells by introducing small interfering and short hairpin RNAs, and examined the gene expression profiles in the cells by microarray analysis. We analyzed the energy-producing pathways in the cells by XFe Extracellular Flux Analyzers, and detected intracellular metabolites by capillary electrophoresis time-of-flight mass spectrometry. We found that the RNAi-mediated knockdown of PKM2 diminished the proliferative, migratory and tumorigenic ability of the PDAC cell-lines. PKM2 knockdown also resulted in lower glycolytic activities and decreased levels of some intracellular metabolites, such as pyruvate and polyamine; however, it led to elevated levels of reactive oxygen species. Microarray analysis revealed the functional association between PKM2 and the expression of genes that drive the cell cycle. On the whole, the findings of this study demonstrate that PKM2 plays an important role in metabolic activities, as well as in the malignancy of PDAC cells.
KW - Cancer metabolism
KW - Glycolysis
KW - Pancreatic ductal adenocarcinoma
KW - Pyruvate kinase type M2
KW - Warburg effect
UR - http://www.scopus.com/inward/record.url?scp=85041608080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041608080&partnerID=8YFLogxK
U2 - 10.3892/ijo.2018.4258
DO - 10.3892/ijo.2018.4258
M3 - Article
C2 - 29393401
AN - SCOPUS:85041608080
SN - 1019-6439
VL - 52
SP - 881
EP - 891
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 3
ER -